A Phase I Multicenter, Open Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea

Trial Profile

A Phase I Multicenter, Open Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 May 2017

At a glance

  • Drugs Olea pollen allergy immunotherapy (Primary)
  • Indications Rhinoconjunctivitis
  • Focus Adverse reactions
  • Sponsors Bial; Roxall Medizin GmbH
  • Most Recent Events

    • 25 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
    • 02 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top